Cited by 265Phytoestrogen effects and researchMenopause: Health Impacts and TreatmentsCancer survivorship and care

Effect of Soy Phytoestrogens on Hot Flashes in Postmenopausal Women With Breast Cancer: A Randomized, Controlled Clinical Trial

Van Patten, Cheri L., Olivotto, Ivo A., Chambers, G. Keith, Gelmon, Karen A., Hislop, T. Gregory, Templeton, Edith, Wattie, Angela, Prior, Jerilynn C.·2002·Journal of Clinical Oncology

Abstract

PURPOSE: Vasomotor symptoms, such as hot flashes and night sweats, in breast cancer survivors are often worsened by chemotherapy and tamoxifen, and/or the discontinuation of hormone replacement therapy at diagnosis. This study evaluated the acceptability and effectiveness of a soy beverage containing phytoestrogens as a treatment for hot flashes in postmenopausal women with breast cancer. METHODS: A randomized, placebo-controlled, double-blind clinical trial was conducted in postmenopausal women with moderate hot flashes who were previously treated for early-stage breast cancer. Women were stratified for tamoxifen use and randomized to a soy beverage (n = 59) containing 90 mg of isoflavones or to a placebo rice beverage (n = 64). Women recorded the number and severity of hot flashes daily with a daily menopause diary for 4 weeks at baseline and for 12 weeks while consuming 500 mL of a soy or placebo beverage. RESULTS: There were no significant differences between the soy and placebo groups in the number of hot flashes or hot flash scores. However, presumably because of a strong placebo effect, both groups had significant reductions in hot flashes. Mild gastrointestinal side effects were experienced by both groups but occurred with greater frequency and severity with soy. The mean serum genistein concentration at 6 weeks was significantly higher in women who consumed soy (0.61 ± 0.43 μmol/L) compared with placebo (0.43 ± 0.37 μmol/L) (P = .02). Overall acceptability and compliance were high and similar in both groups. CONCLUSION: The soy beverage did not alleviate hot flashes in women with breast cancer any more than did a placebo. Future research into other compounds is recommended to identify safe and effective therapies for hot flashes in breast cancer survivors.

Integrity signals

Registry

Crossref · 10.1200/jco.2002.20.6.1449

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Four cohort studies and three RCTs reported no significant differences in treatment outcomes or rates of adverse effects associated with soy use among women receiving tamoxifen therapy.

    “Four cohort studies [100,103,106,112] and three RCTs [128,130,131] reported no significant differences with respect to treatment outcomes or rates of adverse effects associated with use of soy among women who were receiving tamoxifen therapy.”
  • In one RCT, vaginal spotting was reported in four subjects in the soy group compared to one in the placebo group, but statistical significance was not reported because of low numbers.

    “In one RCT, vaginal spotting was reported in four subjects in the soy group compared to one in the placebo group, but with such low numbers, the statistical significance of this finding was not reported [130].”
  • The most common adverse event associated with soy consumption was mild to moderate gastrointestinal discomfort, usually occurring with comparable frequency in soy and placebo groups.

    “The most common adverse event associated with soy consumption was mild to moderate gastrointestinal discomfort, but this usually occurred with comparable frequency in both the soy and the placebo groups [128,130,131,136,142,147,150]; only in one study was there considerable difference in the frequency of GI upset, 47% in the soy group compared to 22% in the control group [130].”
  • The effect of soy on hot flashes in breast cancer patients is not clear.

    “The effect of soy on hot flashes in breast cancer patients is not clear.”
  • RCTs noted some improvements in hot flashes over time, but not in comparison to placebo.

    “RCTs noted some improvements over time, but not in comparison to placebo [127-131].”

Cited by

Sorted by citations

Authors
Van Patten, C. L., Olivotto, I. A., Chambers, G. K., Gelmon, K. A., Hislop, T. G., Templeton, E., Wattie, A., & Prior, J. C.
Affiliations
  • From the British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver Hospital and Health Sciences Centre, and University of British Columbia, Vancouver, British Columbia, Canada.
  • BC Cancer Agency (CA)
Venue
Journal of Clinical Oncology
Published
2002-03-15
Volume
20
Issue
6
Pages
1449-1455
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2122073186
Cited by
265
References
0
Citations by year
2025: 1 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 1 · 2020: 7 · 2019: 4 · 2018: 8 · 2017: 4 · 2016: 9 · 2015: 10 · 2014: 10 · 2013: 7 · 2012: 7
FWCI
16.74
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • TSpace (University of Toronto) (submittedVersion)
Funders
National Cancer Institute
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Phytoestrogen effects and research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
soy phytoestrogens, hot flashes, postmenopausal women, breast cancer survivors, isoflavones, genistein, tamoxifen, vasomotor symptoms, soy beverage, placebo effect, gastrointestinal adverse effects, menopause
MeSH terms
Breast Neoplasms, Double-Blind Method, Estrogens, Non-Steroidal, Female, Humans, Isoflavones, Middle Aged, Glycine max, Treatment Outcome, Postmenopause, Hot Flashes, Plant Preparations, Phytoestrogens

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review